TABLE 2.
Results of the susceptibility testa
| Strain/plasmid | MBL (subclass) | β-Lactam | Drug MIC (μg/ml)b
|
||||||
|---|---|---|---|---|---|---|---|---|---|
| None | MCR |
TSA |
ASB |
||||||
| 8 μg/ml | 128 μg/ml | 8 μg/ml | 128 μg/ml | 8 μg/ml | 128 μg/ml | ||||
| E. coli DH5α/pBC-IMP-1 | IMP-1 (B1) | MEM | 1 | 0.25 (4) | 0.03 (32) | 1 (1) | 1 (1) | 1 (1) | 0.5 (2) |
| E. coli DH5α/pBC-NDM-1 | NDM-1 (B1) | MEM | 32 | 64 (1) | 16 (2) | 32 (1) | 16 (2) | 64 (1) | 8 (4) |
| E. coli DH5α/pBC-VIM-2 | VIM-2 (B1) | CAZ | 16 | 16 (1) | 8 (2) | 16 (1) | 16 (1) | 16 (1) | 8 (2) |
| E. coli DH5α/pCL-SMB-1 | SMB-1 (B3) | MEM | 32 | 16 (2) | 4 (8) | 32 (1) | 8 (4) | 8 (4) | ≤0.25 (≥128) |
| E. coli BL21(DE3)/pET-AIM-1 | AIM-1 (B3) | MEM | 32 | 16 (2) | 1 (32) | 16 (2) | 8 (4) | 16 (2) | 0.5 (64) |
| E. coli DH5α/pBC-LMB-1 | LMB-1 (B3) | MEM | 0.5 | 0.25 (2) | 0.03 (16) | 0.5 (1) | 0.25 (2) | 0.25 (2) | 0.03 (16) |
| E. coli DH5α/pBC-L1 | L1 (B3) | MEM | 4 | 0.5 (8) | 0.03 (128) | 2 (2) | 0.125 (32) | 1 (4) | 0.03 (128) |
a
MCR, mercaptoacetic acid; TSA, thiosalicylic acid; ASB, 4-amino-2-sulfanylbenzoic acid; MEM, meropenem; CAZ, ceftazidime.
b
Data in parentheses indicate fold reductions in MICs. The values indicating MICs that were reduced 16-fold or more are shown in bold.